Literature DB >> 32122786

Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer.

Mohamed Mady1, Kritika Prasai1, Sri H Tella2, Siddhartha Yadav1, Christopher L Hallemeier3, Sagar Rakshit1, Lewis Roberts4, Mitesh Borad5, Amit Mahipal6.   

Abstract

BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) has been used as an inflammation based prognostic marker for various malignancies. This study evaluated the association between NLR and overall survival (OS) in patients with metastatic gallbladder cancer (GBC)
METHODS: An optimal cut off point for NLR was identified by plotting spline-based hazard ratio curves to identify a threshold effect and patients were divided into two groups, ≥5 or <5. Kaplan-Meier curves were plotted for NLR≥5 and NLR<5 and OS between the two groups.
RESULTS: Of the 231 patients included, 138 (60%) had NLR <5 and 93 (40%) had NLR ≥5. There were no significant differences noted in gender, race, and administration of chemotherapy between the two groups. On univariable analysis, patients with NLR ≥5 had a significantly poor OS compared to those with NLR <5 (Median OS: 3.6 vs 8.7 months, p < 0.001). On multivariable analysis, adjusting for age, performance status, albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, platelet count and no administration of chemotherapy, NLR of ≥5 was associated with a worse OS compared to NLR <5 (HR: 1.70, 95%CI:1.20-2.39, p < 0.05).
CONCLUSION: The current study demonstrates that NLR ≥5 is an independent predictor of poor prognosis in patients with metastatic GBC.
Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32122786     DOI: 10.1016/j.hpb.2020.02.002

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  7 in total

1.  Prognostic Nomograms to Predict Survival of Patients with Resectable Gallbladder Cancer: A Surveillance, Epidemiology, and End Results (SEER)-Based Analysis.

Authors:  Yan Lin; Hua Chen; Fan Pan
Journal:  Med Sci Monit       Date:  2021-03-30

2.  Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors.

Authors:  Rui Huang; Yanfen Zheng; Wenxue Zou; Chao Liu; Jibing Liu; Jinbo Yue
Journal:  J Immunol Res       Date:  2022-08-17       Impact factor: 4.493

3.  Risk factors and prognosis of liver metastasis in gallbladder cancer patients: A SEER-based study.

Authors:  Cheng Fang; Wenhui Li; Qingqiang Wang; Ruoran Wang; Hui Dong; Junjie Chen; Yong Chen
Journal:  Front Surg       Date:  2022-08-23

4.  Prognostic Value of the Albumin-to-γ-glutamyltransferase Ratio for Gallbladder Cancer Patients and Establishing a Nomogram for Overall Survival.

Authors:  Lejia Sun; Xindi Ke; Dongyue Wang; Huanhuan Yin; Bao Jin; Haifeng Xu; Shunda Du; Yiyao Xu; Haitao Zhao; Xin Lu; Xinting Sang; Shouxian Zhong; Huayu Yang; Yilei Mao
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

5.  Prognostic Value of Peripheral Whole Blood Cell Counts Derived Indexes in Gallbladder Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Bowen Xu; Zhiqiang Chen; Jing Zhang; Jianhua Chang; Wei Zhao; Zhaoru Dong; Xuting Zhi; Tao Li
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

6.  Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit.

Authors:  Lin Li; Tai Ren; Ke Liu; Mao-Lan Li; Ya-Jun Geng; Yang Yang; Huai-Feng Li; Xue-Chuan Li; Run-Fa Bao; Yi-Jun Shu; Hao Weng; Wei Gong; Wan Yee Lau; Xiang-Song Wu; Ying-Bin Liu
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

7.  Diagnostic Value of Inflammatory Factors in Patients with Gallbladder Cancer, Dysplasia, and Cholecystitis.

Authors:  Sirin Kucuk; Soycan Mızrak
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.